<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002595</url>
  </required_header>
  <id_info>
    <org_study_id>LGH-1011</org_study_id>
    <secondary_id>CDR0000063797</secondary_id>
    <secondary_id>NCI-V91-0211</secondary_id>
    <nct_id>NCT00002595</nct_id>
  </id_info>
  <brief_title>Toremifene in Treating Patients With Desmoid Tumors</brief_title>
  <official_title>PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advocate Lutheran General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using&#xD;
      toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of toremifene in treating patients with&#xD;
      desmoid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of toremifene in terms of tumor response rate and&#xD;
      symptom relief in patients with desmoid tumors. II. Determine the safety of this regimen in&#xD;
      these patients. III. Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified by gender. Patients receive oral toremifene daily until&#xD;
      complete or maximal response in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients achieving maximal response undergo complete resection of all lesions, if feasible.&#xD;
      Nonsurgical candidates with severe or life-threatening disease not achieving partial or&#xD;
      complete response or symptom relief at 12 months may continue on toremifene at the discretion&#xD;
      of the study chairperson. Patients with stable disease who do not undergo surgery may&#xD;
      continue on toremifene for a maximum of 12 months at the discretion of the treating&#xD;
      physician. Patients who continue to experience symptom relief at 12 months may continue on&#xD;
      toremifene at the discretion of the study chairperson. Quality of life is assessed at&#xD;
      baseline and at 2 and 6 months. Patients are followed every 8 weeks for 4 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-72 (12-36 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1991</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Desmoid Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toremifene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven primary or recurrent desmoid tumor&#xD;
        Unresectable and symptomatic or progressive disease OR Disease for which a mutilating&#xD;
        surgery would be required for complete resection Bidimensionally measurable or clinically&#xD;
        evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over (no prepubertal patients) Performance status: 0-2&#xD;
        Life expectancy: More than 2 months Hematopoietic: Absolute granulocyte count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL&#xD;
        Transaminases no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no&#xD;
        greater than 3 times ULN Renal: Not specified Cardiovascular: No history of deep vein&#xD;
        thrombosis Other: Not pregnant Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified&#xD;
        Endocrine therapy: No concurrent dexamethasone for antiemesis No other concurrent hormonal&#xD;
        therapy, including hormonal contraceptives Radiotherapy: Not specified Surgery: See Disease&#xD;
        Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian L. Samuels, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Advocate Lutheran General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>desmoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

